Saksham Pharmaceuticals (India) Limited, a active public limited company, was established on 01 March 2011 in Burari, Delhi, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U24232DL2011PLC215019. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹1.00 Cr and a paid-up capital of ₹1.00 Cr.
It upholds a compliant status. Employing 6 professional, Its leadership includes Neelam Jain (Director), Ankur Jain (Director), Saksham Jain (Additional Director). Past directors included Pawan Kumar, Durgesh Verma, Surinder Oberoi. It holds ₹1.23 Cr open charges and ₹3.10 M settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at First Floor, Out Of Khasra No. 19/26 At Main 100 Foota Road, Kaushik Enclave, Burari, Delhi, 110084.
U24232DL2011PLC215019
215019
01 March 2011
₹1.00 Cr
₹1.00 Cr
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Saksham Pharmaceuticals (India) Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Neelam Jain | Director | 01 Mar 2011 | Current |
| Ankur Jain | Director | 01 Mar 2011 | Current |
| Saksham Jain | Additional Director | 07 Dec 2024 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 05 Dec 2011 | Past |
| Pramod Abcsdd | Director | 17 Jul 2012 | Past |
| Pramod Abcsdd | Director | 18 Dec 2012 | Past |
| Pramod Abcsdd | Director | 09 Aug 2014 | Past |
| Pramod Abcsdd | Director | 17 Dec 2021 | Past |
| Pramod Abcsdd | Director | 04 Aug 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Saksham Pharmaceuticals (India) Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.57% increase. The company also saw a substantial improvement in profitability, with a 106.36% increase in profit. The company's net worth moved up by a moderate rise of 2.92%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Saksham Pharmaceuticals (India) had a promoter holding of 60.85% and a public holding of 39.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹12,261,550.00
₹3,100,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Jun 2019 | Others | ₹1.23 Cr | Open |
| 23 Sep 2014 | Hdfc Bank Limited | ₹3.10 M | Satisfied |
Explore comprehensive loan charge details -
Saksham Pharmaceuticals (India) has a workforce of 6 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Saksham Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Saksham Pharmaceuticals (India)'s trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Saksham Jain was appointed as a Additional Director was appointed as a Additional Director on 07 Dec 2024 & has been associated with this company since 11 months 29 days . was completed.
Saksham Pharmaceuticals (India) Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was recorded as a recent event.
Progress on Saksham Pharmaceuticals (India) Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was documented.
The activity A charge registered on 23 Sep 2014 via Charge ID 10522329 with Hdfc Bank Limited was fully satisfied on 29 Mar 2023. was completed.
Progress on A charge with Others of Rs. 1.23 Cr registered on 25 Jun 2019 with Charge ID 100273651 was modified on 23 Sep 2021. was documented.
The activity A charge with Others amounted to Rs. 1.23 Cr with Charge ID 100273651 was registered on 25 Jun 2019. was completed.
The CIN of Saksham Pharmaceuticals (India) Limited is U24232DL2011PLC215019.
Saksham Pharmaceuticals (India) Limited is headquartered at First Floor, Out Of Khasra No. 19/26 At Main 100 Foota Road, Kaushik Enclave, Burari, Delhi, 110084.
Saksham Pharmaceuticals (India) Limited was incorporated on 01 March 2011.
The current directors of Saksham Pharmaceuticals (India) Limited are
The primary industry of Saksham Pharmaceuticals (India) Limited is Trade.
Saksham Pharmaceuticals (India) Limited is unlisted.
The authorized capital of Saksham Pharmaceuticals (India) Limited is ₹1.00 Cr, and the paid-up capital is ₹1.00 Cr.
The compliance status of Saksham Pharmaceuticals (India) Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
_LIMITED_379234.webp)
Company Details
+91-XXXXXXXXXX